Pfizer covid vaccine for new variants: October 2022

Ugur Sahin, CEO and co-founder of BioNTech.

BioNTech and Pfizer announced on Monday that its Covid-19 vaccine suitable for BA.1 and BA.4/5 variants they will only arrive October 2022, “in time for fall booster campaigns”.

This is how BioNTech advanced in the presentation of its financial results for the first half of 2022which includes second-quarter 2022 revenue of €3,200 million, with net income of €1,700 million, as well as first-half 2022 revenue of €9,600 million , with a net profit of 5,400 million euros.

More specifically on its vaccine against Covid-19, its forecast is to enter between 13,000 and 17,000 million euros in 2022. This revenue estimate reflects projected revenue related to BioNTech’s share of gross profit from sales of the vaccine in collaborating partner territories, direct sales of the vaccine to customers in BioNTech’s territory, and projected revenue generated from the products. manufactured by BioNTech and sold to collaborating partners.

“In the first half of 2022, we achieved significant milestones by further strengthening our vaccine leadership, expanding our broad product pipeline and accelerating its maturation. Our Covid-19 product portfolio includes variant-matched and next-generation vaccine candidates aimed at broad-based, long-term protection. In oncology, we presented encouraging updates of data from our individualized mRNA cancer vaccine candidate BNT122 in pancreatic cancer and our new cell therapy candidate BNT211 CAR-T in solid tumors, which led to our first PRIME designation by the EMA. We are moving towards preparing for registration trials, as well as delivering our first BioNtainers to Africa, with the aim of providing access to new drugs,” said BioNTech CEO and co-founder Ugur Sahin. .

“Thanks to the good results obtained to date, we believe that we are on track to achieve our financial forecasts for the current year. key markets in the fourth quarter of 2022, subject to regulatory approval. We will continue to invest heavily in research and development in 2022 and beyond, and will remain focused on growing our oncology product portfolio., as well as promoting our leadership in the development of the Covid-19 vaccine. We are driving the potential launch of several innovative products to treat diseases with high unmet medical need over the next three to five years,” added BioNTech CFO Jens Holstein.

Although it may contain statements, data, or notes from healthcare institutions or professionals, the information in Medical Writing is edited and prepared by journalists. We recommend that the reader consult a healthcare practitioner with any health-related questions.

Leave a Comment